Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Arbutus Biopharma Corporation (ABUS) Insider Trading Activity
Healthcare • Biotechnology • 73 employees
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Total Value
-$241,655.08
Total Shares
294,046
Average Trade Value
-$30,206.89
Most Active Insider
Mc Elhaugh Michael J.
Total Activity: $88,103
Largest Single Transaction
$78,103
by Mc Elhaugh Michael J. on Feb 4, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
General Counsel and Cco
Officer
|
Feb 14, 2025 | 54,300 | $0 | 140,544 (+38.6%) | Grant | |
|
Chief Financial Officer
Officer
|
Feb 14, 2025 | 90,100 | $0 | 249,824 (+36.1%) | Grant | |
|
Chief Medical Officer
Officer
|
Feb 14, 2025 | 49,300 | $0 | 155,494 (+31.7%) | Grant | |
|
Interim President CEO
Director, Officer
|
Feb 14, 2025 | 177,000 | $10,000 | 1,658,003 (+10.7%) | Grant | |
|
Interim President CEO
Director, Officer
|
Feb 4, 2025 | 23,790 | $78,103 | 1,481,003 (-1.6%) | Sale | |
|
Chief Medical Officer
Officer
|
Feb 4, 2025 | 19,348 | $63,519 | 106,194 (-18.2%) | Sale | |
|
Chief Financial Officer
Officer
|
Feb 4, 2025 | 22,183 | $72,827 | 159,724 (-13.9%) | Sale | |
|
General Counsel and Cco
Officer
|
Feb 4, 2025 | 11,333 | $37,206 | 86,244 (-13.1%) | Sale |